טוען...
A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel
OBJECTIVES. This study aimed to evaluate the efficacy and safety of once-per-cycle balugrastim versus pegfilgrastim for neutrophil support in breast cancer patients receiving myelosuppressive chemotherapy. METHODS. Breast cancer patients (n = 256) were randomized to 40 or 50 mg of subcutaneous balug...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AlphaMed Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4709202/ https://ncbi.nlm.nih.gov/pubmed/26668251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0152 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|